SANTA MONICA, Calif. , Oct. 06, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the last patient has been enrolled in the Phase 2 clinical trial of

SANTA MONICA, Calif. , Aug. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Opiant’s pipeline candidate OPNT004 (drinabant) for the treatment of

SANTA MONICA, Calif. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022 ,

SANTA MONICA, Calif. , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional approximately $2.1 million to support OPNT003, nasal nalmefene, for the

SANTA MONICA, Calif. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (Opiant) (NASDAQ: OPNT) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/461,354, with formulation and method of use claims

SANTA MONICA, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc.  (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter

SANTA MONICA, Calif. , June 28, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation and Human Capital Committee of the Company’s

Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003 SANTA MONICA, Calif. , June 08, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (Opiant) (NASDAQ: OPNT) today announced a capacity investment

Company expects to complete submission of the NDA using the 505(b)(2) pathway, as previously agreed upon with the FDA, in the second half of 2022 SANTA MONICA, Calif. , June 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (Opiant) (NASDAQ: OPNT) today announced the filing of the first

SANTA MONICA, Calif. , May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will